Literature DB >> 11465584

Distribution of the probability of survival is a strategic issue for randomized trials in critically ill patients.

B Riou1, P Landais, B Vivien, P Stell, I Labbene, P Carli.   

Abstract

BACKGROUND: Many randomized clinical trials in trauma have failed to demonstrate a significant improvement in survival rate. Using a trauma patient database, we simulated what could happen in a trial designed to improve survival rate in this setting.
METHODS: The predicted probability of survival was assessed using the TRISS methodology in 350 severely injured trauma patients. Using this probability of survival, the authors simulated the effects of a drug that may increase the probability of survival by 10-50% and calculated the number of patients to be included in a triad, assuming alpha = 0.05 and beta = 0.10 by using the percentage of survivors or the individual probability of survival. Other distributions (Gaussian, J shape, uniform) of the probability of survival were also simulated and tested.
RESULTS: The distribution of the probability of survival was bimodal with two peaks (< 0.10 and > 0.90). There were major discrepancies between the number of patients to be included when considering the percentage of survivors or the individual value of the probability of survival: 63,202 versus 2,848 if the drug increases the probability of survival by 20%. This discrepancy also occurred in other types of distribution (uniform, J shape) but to a lesser degree, whereas it was very limited in a Gaussian distribution.
CONCLUSIONS: The bimodal distribution of the probability of survival in trauma patients has major consequences on hypothesis testing, leading to overestimation of the power. This statistical pitfall may also occur in other critically ill patients.

Entities:  

Mesh:

Year:  2001        PMID: 11465584     DOI: 10.1097/00000542-200107000-00014

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  10 in total

1.  The clinical trials of diaspirin cross-linked hemoglobin (DCLHb) in severe traumatic hemorrhagic shock: the tale of two continents.

Authors:  Edward P Sloan
Journal:  Intensive Care Med       Date:  2003-03       Impact factor: 17.440

2.  Analysis of the medical response to November 2015 Paris terrorist attacks: resource utilization according to the cause of injury.

Authors:  Mathieu Raux; Pierre Carli; Frédéric Lapostolle; Matthieu Langlois; Youri Yordanov; Anne-Laure Féral-Pierssens; Alexandre Woloch; Carl Ogereau; Etienne Gayat; Arié Attias; Dominique Pateron; Yves Castier; Anne François; Bertrand Ludes; Emmanuelle Dolla; Jean-Pierre Tourtier; Bruno Riou
Journal:  Intensive Care Med       Date:  2019-08-15       Impact factor: 17.440

3.  Comparison of respiratory rate and peripheral oxygen saturation to assess severity in trauma patients.

Authors:  Mathieu Raux; Michel Thicoïpé; Eric Wiel; Elisabeth Rancurel; Dominique Savary; Jean-Stéphane David; Frédéric Berthier; Agnès Ricard-Hibon; Frédéric Birgel; Bruno Riou
Journal:  Intensive Care Med       Date:  2006-02-17       Impact factor: 17.440

4.  DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" multicenter study.

Authors:  Thoralf Kerner; Olaf Ahlers; Siegfried Veit; Bruno Riou; Michael Saunders; Ulrich Pison
Journal:  Intensive Care Med       Date:  2003-01-23       Impact factor: 17.440

5.  Impact of whole-body computed tomography on mortality and surgical management of severe blunt trauma.

Authors:  Jean-Michel Yeguiayan; Anabelle Yap; Marc Freysz; Delphine Garrigue; Claude Jacquot; Claude Martin; Christine Binquet; Bruno Riou; Claire Bonithon-Kopp
Journal:  Crit Care       Date:  2012-06-11       Impact factor: 9.097

Review 6.  Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma.

Authors:  Alicia M Mohr; John B Holcomb; Richard P Dutton; Jacques Duranteau
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

7.  Medical pre-hospital management reduces mortality in severe blunt trauma: a prospective epidemiological study.

Authors:  Jean-Michel Yeguiayan; Delphine Garrigue; Christine Binquet; Claude Jacquot; Jacques Duranteau; Claude Martin; Fatima Rayeh; Bruno Riou; Claire Bonithon-Kopp; Marc Freysz
Journal:  Crit Care       Date:  2011-01-20       Impact factor: 9.097

8.  Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials.

Authors:  Sandro B Rizoli; Kenneth D Boffard; Bruno Riou; Brian Warren; Philip Iau; Yoram Kluger; Rolf Rossaint; Michael Tillinger
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

9.  Relationship between Obesity and Massive Transfusion Needs in Trauma Patients, and Validation of TASH Score in Obese Population: A Retrospective Study on 910 Trauma Patients.

Authors:  Audrey De Jong; Pauline Deras; Orianne Martinez; Pascal Latry; Samir Jaber; Xavier Capdevila; Jonathan Charbit
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

10.  Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients.

Authors:  Julien Pottecher; Eric Noll; Marie Borel; Gérard Audibert; Sébastien Gette; Christian Meyer; Elisabeth Gaertner; Vincent Legros; Raphaël Carapito; Béatrice Uring-Lambert; Erik Sauleau; Walter G Land; Seiamak Bahram; Alain Meyer; Bernard Geny; Pierre Diemunsch
Journal:  Trials       Date:  2020-03-18       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.